Visualizing mitochondrial FoF1-ATP synthase as the target of the
  immunomodulatory drug Bz-423 by Starke, Ilka et al.
Visualizing mitochondrial FoF1-ATP synthase as the target of the immunomodulatory drug 
Bz-423 
 
Ilka Starke1,2, Gary D. Glick3, Michael Börsch1,4 
1 Single-Molecule Microscopy Group, Jena University Hospital, Friedrich Schiller University, 
Nonnenplan 2 - 4, 07743 Jena, Germany 
2 Institute for Physical Chemistry, Albert Ludwig University Freiburg, Albertstrasse 23a, 79104 
Freiburg, Germany 
3 Department of Chemistry, University of Michigan, 930 N University Ave, Ann Arbor, MI 48109-1055, 
USA 
4 Abbe Center of Photonics (ACP), Jena, Germany 
 
 
Abstract 
Targeting the mitochondrial enzyme FoF1-ATP synthase and modulating its catalytic activities with small 
molecules is a promising new approach for treatment of autoimmune diseases. The immuno-
modulatory compound Bz-423 is such a drug that binds to subunit OSCP of the mitochondrial FoF1-ATP 
synthase and induces apoptosis via increased reactive oxygen production in coupled, actively respiring 
mitochondria. Here we review the experimental progress to reveal the binding of Bz-423 to the 
mitochondrial target and discuss how subunit rotation of FoF1-ATP synthase is affected by Bz-423. 
Briefly, we report how Förster resonance energy transfer (FRET) can be employed to colocalize the 
enzyme and the fluorescently tagged Bz-423 within the mitochondria of living cells with nanometer 
resolution. 
 
  
1. Introduction 
Cellular processes as metabolism and transport are powered by the universal chemical “energy 
currency” that is the molecule adenosine triphosphate (ATP). Therefore, millimolar ATP concentrations 
inside the cell have to be produced and maintained through sequential catalytic reactions by the 
glycolysis pathway or more efficiently by the FoF1-ATP synthase as part of the oxidative 
phosphorylation (OXPHOS) pathway. FoF1-ATP synthases are working in the plasma membrane of 
bacteria or in small organelles inside of eukaryotes, i.e. the thylakoid membrane in chloroplasts or the 
inner mitochondrial membrane. In case of mitochondrial FoF1-ATP synthase a proton motive force 
(PMF) comprising a concentration difference of protons across the membrane (pH) plus an electric 
membrane potential ( is required for ATP synthesis. The PMF is generated by sequential redox 
processes and associated proton pumping of the enzyme complexes I to IV of the respiratory chain 
across the inner mitochondrial membrane. 
If we consider autoimmune diseases, for example systemic lupus erythematodes, being caused by 
hyperactivity of pathogenic T cells of the immune system, then controlling their cellular ATP 
concentration with drugs and reducing their activity could become a promising approach for clinical 
treatment. Modulating T cell activity temperately could circumvent a complete shut-down of the 
normal immune function. Therefore, one option would be controlling the PMF by targeting any of the 
enzyme complexes I to IV of the respiratory chain with inhibitors. Vice versa, controlling the efficiency 
of converting PMF to ATP synthesis by FoF1-ATP synthase would be a possible approach. This latter 
process is called uncoupling.  
More than a decade ago, a 1,4-benzodiazepine, Bz-423 (Figure 1 A), has been found to target lymphoid 
cells in a murine model of lupus erythematodes[1]. Bz-423 specifically induced apoptosis of pathogenic 
lymphocytes and attenuated disease progression. As a result, the treated mice showed a prolonged 
survival at the therapeutic dosage without adverse toxicity and with maintained immune function[2]. 
The mechanism of Bz-423 action was revealed and subsequently the molecular target was identified – 
the mitochondrial FoF1-ATP synthase[3]. Here we focus on the discovery of the drug binding site and 
discuss a recent microscopy approach using Förster resonance energy transfer (FRET) that has directly 
demonstrated the binding of a fluorescent Bz-423 derivative to the mitochondrial enzyme in living 
cells[4]. 
 
2. Bz-423 binds to OSCP of mitochondrial FoF1-ATP synthase  
Initially, Bz-423 was identified as a potential drug candidate from a library of 1,4-benzodiazepines 
generated by diversity-oriented chemical synthesis[1]. Phenotype screening of Ramos B cells revealed 
that Bz-423 caused cell shrinkage, nuclear condensation, cytoplasmic vacuolization, membrane 
blebbing and DNA fragmentation. Other 1,4-benzodiazepine derivatives were found to selectively 
target T-cells[5-8]. Bz-423 did not strongly bind to the peripheral benzodiazepine receptor. Cytotoxicity 
of Bz-423 was related to rapidly generated superoxide (O2.-) in mitochondria. Superoxide is one of the 
reactive oxygen species (ROS) that can chemically damage cellular macromolecules at higher 
concentrations. However, Bz-423 superoxide signaling for induced apoptosis was proven as the 
underlying mechanisms[9, 10]. 
In the presence of 1 mM sodium azide, the proapoptotic O2.- generation by Bz-423 was abolished[1]. 
Because sodium azide is an inhibitor of cytochrome c oxidase, i.e. complex IV of the mitochondrial 
respiratory chain, Bz-423 was proposed to bind to a mitochondrial OXPHOS protein. Binding of Bz-423 
did not alter or collapse the electric potential  across the inner mitochondrial membrane. The 
superoxide response by Bz-423 required active mitochondria in state 3 respiration, but not 
mitochondria in state 4 with minimal respiration and in the absence of ADP. Comparing the superoxide 
generation mechanism induced by oligomycin that induces a state-3-to-4 transition of mitochondrial 
respiration[11] lead to the hypothesis that Bz-423 might cause a state-3-to-4 transition as well and 
might bind to FoF1-ATP synthase. 
The validation of FoF1-ATP synthase as the mitochondrial target of Bz-423 was achieved by phage 
display screening[3]. Briefly, the oligomycin sensitivity conferring protein (OSCP) being a subunit of 
FoF1-ATP synthase was determined. Subsequently the binding site of Bz-423 was located by NMR 
spectroscopy using the isolated subunit OSCP in solution[12]. Figure 1 A shows the model of bovine 
heart FoF1-ATP synthase with the highlighted subunit OSCP in green and the amino acid residues 
involved in binding of Bz-423 as red dots. Accordingly Bz-423 binds to the top of the membrane enzyme 
at the interface of OSCP with one pair of  subunits (blue in Fig. 1 A) of the F1 part. Binding of water-
soluble Bz-423 analogues to OSCP in a chemical shift perturbation NMR measurement revealed specific 
residues 51, 55, 65, 66, 75, 77 and 92 that might form a hydrophobic pocket to accommodate the drug. 
Furthermore, Bz-423 binding resulted in a conformational rearrangement of helices in OSCP and might 
alter the interaction of OSCP with F1 in an allosteric manner[12]. 
 
 
Figure 1: A, model of the mitochondrial FoF1-ATP synthase from bovine heart with binding site for Bz-423 (red dots) on subunit 
OSCP (in green, on the top; from cryoEM data, PDB 5ARA [13]). Subunits  and  are shown in blue and the rotary subunits 
,  and  in orange of the F1 part. The peripheral stator consists of subunits b, d, F6 and A6L (in silver). The proton-translocating 
subunit a is depicted in black, and the rotor ring of eight c subunits is shown in yellow. B, structure of OSCP from bovine heart 
(from x-ray crystallographic data, PDB 2WSS [14]) with highlighted residues 51, 55, 65, 66, 75, 77 and 92 shown to be involved 
in Bz-423 binding. C, Bz-423 derivative with the 1,4-benzodiazepine moiety highlighted by the bluish box, a flexible hexyl 
linker L (grey ellipse) and the FRET acceptor fluorophore Cy5 (red ellipse). Bz-423-Cy5 is expected to bind to OSCP of the yeast 
mitochondrial FoF1 (red dots on the top of the monomer of the yeast enzyme, cryoEM data, PDB 6B8H [15]). The FRET donor 
yeast-enhanced green fluorescent protein (yEGFP) is fused to the extended C-terminus of the -subunit (symbolized by the 
green box). 
  
3. Bz-423 requires OSCP to modulate FoF1-ATP synthase activity in vitro and in cells 
Binding of Bz-423 to OSCP in the intact FoF1-ATP synthase inhibited both synthesis and hydrolysis of 
ATP in isolated sub-mitochondrial particles (SMP) in vitro[3, 16]. Both maximal turnover Vmax and KM 
were changed, in contrast to the inhibitor oligomycin which reduced Vmax only. ATP hydrolysis by the 
soluble mitochondrial F1 part (comprising the blue and orange colored subunits the Fig. 1 A) was 
reduced but only when F1 was assembled with OSCP. The IC50 for Bz-423 was about 5 µM. In perfused 
HEK cells ATP synthesis rates of mitochondria were reduced, with IC50 of less than 5 µM for Bz-423. 
Engineered HEK cells with a specifically reduced content of OSCP by siRNA showed alleviated apoptosis 
by Bz-423, and the residual amount of cellular OSCP correlated well with the percentage of apoptotic 
cells[3].  
FoF1-ATP synthase accomplishes ATP synthesis by mechanochemical energy conversion with two rotary 
subunit motors. The PMF drives the Fo motor when protons enter the half-channel of the membrane-
embedded a subunit (black in Fig. 1 A) from the intermembrane space, i.e. from below. Binding to a 
specific residue on one c subunit (yellow in Fig. 1A) compensates electrostatic forces and allows the 
ring of c subunits to rotate one step forward. Rotation of the c-ring moves the elastically-coupled 
attached F1 motor (orange in Fig. 1 A comprising subunits , , and ). The F1 motor rotates in three 
120° steps at high PMF and stops at each of the three catalytic sites where ATP is synthesized in F1. 
These distinct step sizes of the rotary Fo and F1 motors during ATP synthesis have been measured in 
vitro in single-molecule experiments using bacterial FoF1-ATP synthases[17-19]. FoF1-ATP synthase can 
also run in reverse by hydrolyzing ATP. ATP hydrolysis has been used to investigate the F1 motor in 
great detail since 20 years[20] and revealed torque, elastic domains[21, 22], substeps[23, 24], breaks 
and other motor properties[25-27].  
Internal subunit rotation with high torque requires a mechanically stable stator counterpart of the 
enzyme. The stator of the mitochondrial FoF1-ATP synthase comprises the six F1 subunits 33 (blue in 
Fig. 1 A), subunits b, d, F6, A6L (silver in Fig. 1 A), the a subunit (black in Fig. 1 A) and OSCP (green in 
Fig. 1 A). Binding of Bz-423 to the interface of OSCP with 33 might weaken the stator assembly and 
might cause transient uncoupling of the F1 and Fo motors. Alternatively, Bz-423 might influence the 
subtle conformational changes of OSCP bound to the top part of the catalytic 33 subunits and 
thereby provokes reduced rates of ATP synthesis and hydrolysis. Quantitative enzymatic analysis 
revealed that Bz-423 is an uncompetitive inhibitor of mitochondrial FoF1-ATP synthase decreasing Vmax 
for ATP synthesis to 50% in the presence of ~10 µM Bz-423[16]. Inhibition by µM amounts of Bz-423 
corresponded to fast off-rates < 0.3 s-1 of the drug from FoF1-ATP synthase and a 90% recovery of ATP 
synthesis rates after 10 seconds. 
 
4. Imaging the drug and its molecular target in mitochondria 
Localizing a drug at a specific target in life cells can be achieved using fluorescence microscopy with 
high spatial and temporal resolution as well as single molecule sensitivity. A variety of functional Bz-
423 derivatives was synthesized with a flexible linker to rhodamine- or cyanine fluorophores, for 
example Bz-423-Cy5 (Fig. 1 C). Because µM concentrations of Bz-423 are required to bind to OSCP and 
to induce apoptosis, direct imaging of the fluorescent drug bound to FoF1-ATP synthase in the inner 
mitochondrial membrane is not possible due to a high fluorescent background of unbound Bz-423 
throughout the cell. Fast off-rates of Bz-423 and its fluorescent derivatives prevent extensive washing 
of the cells which is needed to obtain a good imaging contrast. Therefore, confocal microscopy with 
about 250 nm resolution or superresolution microscopies like structured illumination SIM 
[28](resolution limit of about 100 nm) or stimulated emission depletion STED [29](resolution limit of 
about 20 nm) cannot be used to identify bound Bz-423 on OSCP. 
Instead, Förster resonance energy transfer[30, 31] (FRET) as a distance measurement approach in the 
2 to 9 nanometer range is applicable. The dipole-dipole interaction of FRET between to nearby 
fluorophores causes a relative loss of fluorescence intensity of the FRET donor (excited by the laser) 
and an increase of fluorescence intensity of the FRET acceptor. Thus FRET can be used to relate the 
spatial position of the fluorescently labelled drug to its cellular target that is tagged with a different 
fluorophore. Mitochondrial FoF1-ATP synthase can be tagged with fluorescent proteins, for example at 
OSCP[32] or at the rotary  subunit without affecting function[33-35]. The benefit of using a genetic 
fusion to the enzyme is a negligible fluorescent background from other parts of the cell than the cristae 
of the inner mitochondrial membrane. 
 
5. Revealing Bz-423-Cy5 binding to FoF1-ATP synthase by FRET acceptor photobleaching 
To detect binding of fluorescent Bz-423 to mitochondrial FoF1-ATP synthase in living S. cerevisiae cells, 
we used a FoF1-ATP synthase mutant designed by J. Petersen and P. Gräber (Albert Ludwig University 
Freiburg, to be published). A fusion of the yeast-enhanced green fluorescent protein (yEGFP) linked to 
the C-terminus of the  subunit (Fig. 1 C) provided the donor for FRET imaging (Fig. 2). The fully 
functional mutant was checked for ATP synthesis, and catalytic rates were also determined in vitro 
after protein purification and reconstitution to liposomes. Staining mitochondria was achieved by 
incubating the S. cerevisiae cells with 4 µm Bz-423-Cy5 (see structure in Fig. 1 C) in the presence of 2% 
EtOH for 8 h at 28°C. After washing, the bluish cells (Fig. 2 E) were imaged immediately on the 
microscope at 22°C[4]. 
Widefield fluorescence microscopy of the stained yeast showed spherical cells with bright spots 
suggesting fluorescent FoF1-ATP synthase in mitochondria (Fig. 2 A). SIM imaging of unstained yeast 
confirmed that only mitochondria were fluorescent[4]. Repeated imaging of the same field of view 
indicated comparable pixel intensities in these cells revealing only minor photobleaching of yEGFP. 
However, subsequent excitation of the cells with 640 nm at high power photobleached the FRET 
acceptor Cy5 dye on Bz-423, and the loss of FRET acceptor resulted in an increase of the FRET donor 
intensity when imaged again with 488 nm (Fig. 2 B). Stepwise photobleaching of Cy5 correlated with 
an stepwise increase of FRET donor fluorescence (Fig. 2 C, D). Analysis of the intensity increase in 
individual cells (see histograms of the single cell highlighted by the red circle in Fig. 2 A-D) due to Cy5 
photobleaching unequivocally corroborated the binding of Bz-423-Cy5 to a position on FoF1-ATP 
synthase only few nm away from the yEGFP chromophore at the extended C-terminus of the  subunit. 
Most likely, Bz-423-Cy5 was bound to OSCP. 
FRET acceptor photobleaching to confirm the molecular target of a drug in living cells is a fluorescence 
microscopy approach that requires fast imaging capability but not necessarily high photon counts rates 
per pixel to achieve accurate colocalization. Despite weak (µM) binding affinities of Bz-423-Cy5 and 
fast exchange of the immunomodulator on OSCP, a significant fraction of bound Bz-423-Cy5 was 
revealed by FRET. Slow transport of Bz-423 across the membranes into the matrix of mitochondria as 
the final destination was indicated by long incubation times needed for staining the yeast cells (Fig. 2 
E). Accordingly, a significant fraction of Bz-423-Cy5 still remained in the cytosol and outside of the 
mitochondria during FRET acceptor photobleaching, and did not contribute to apoptotic action. 
However, slow exchange of photobleached Bz-423-Cy5 into and out of the matrix compartment 
facilitated the FRET detection. 
 Figure 2: FRET acceptor photobleaching of Bz-423-Cy5 bound to mitochondrial FoF1-ATP synthase with yEGFP fusion to the  
subunit in living S. cerevisiae[4]. EMCCD-based widefield fluorescence microscopy used laser excitation of yEGFP with 488 nm 
and fluorescence detection of yEGFP between 500 to 550 nm. A – D, sequential imaging of yEGFP-tagged FoF1-ATP synthases 
with recalculated, false-colored intensities in 8 bit (0 – 255). Between each image, a 30-s high-power laser pulse with 640 nm 
was applied to partially photobleach the Cy5 chromophore. The individual pixel intensities of the highlighted cell (red circle 
as the region-of-interest ROI) are plotted in the histogram in the lower panel as recorded by the EMCCD camera. E, 
comparison of S. cerevisiae cells without Bz-423 on the left and stained with 4 µM Bz-423-Cy5 on the right (modified from [4] 
with permission). 
 
 
6. Future developments 
Following the first demonstration that the 1,4-benzodiazepine Bz-423 induced apoptosis in living B 
cells by stimulating superoxid production of the OXPHOS complexes[1] the identification of its 
molecular target in mitochondria was accomplished by biochemical methods. Subunit OSCP of FoF1-
ATP synthase being the destination of the drug was unraveled by human cDNA T7 phage display 
screening. Genetic removal of OSCP in mutant FoF1-ATP synthases proved that apoptosis required 
binding of Bz-423 to this subunit. Using purified soluble OSCP, the amino acids involved in the binding 
site were discovered by NMR spectroscopy[12]. 
A detailed view on the Bz-423 binding site at the interface of OSCP with the N-termini of  and  
subunits of F1 is permitted by the recent high-resolution CryoEM structures of the complete 
mitochondrial enzymes from bovine heart and from yeast S. cerevisiae[13, 15]. Both OSCP and the N-
termini of  and  subunits change their conformations during catalysis, and Bz-423 binding might 
interfere with these changes and might retard the turnover. Subsequently the mitochondrial PMF 
builds up, mitochondria switch from respirational state 3 to 4, superoxide is produced, and Ca2+ 
signaling and apoptosis are initiated. Bz-423 induced the opening of the mitochondrial permeability 
transition pore and thus decreased the Ca2+ retention capability[36-38].  
The weak binding affinities of Bz-423 and its fluorescent derivatives like Bz-423-Cy5 prevented direct 
fluorescence microscopy approaches in living cells. In initial confocal microscopy experiments we 
noticed a broad spatial distribution of Bz-423-Cy5 in S. cerevisiae cells but not a specific staining of the 
mitochondria. Therefore we evaluated the use of sub-mitochondrial particles with fluorescently 
tagged FoF1-ATP synthase for FRET in vitro but failed to detect sensitized FRET acceptor emission due 
to the high fluorescent background of unbound Bz-423-Cy5. The solution for a FRET-based direct 
detection of Bz-423 binding to OSCP was FRET acceptor photobleaching in mitochondria of living cells. 
Here the pool of unbound Bz-423-Cy5 is limited, and photobleaching Cy5 with 640 nm at high power 
is possible without destroying the FRET donor fluorophore yEGFP on FoF1-ATP synthase. Now, similar 
FRET experiment are under way with human HEK cells and by using the brightest and more photostable 
green fluorescent protein mNeonGreen[39] fused to the C-terminus of the  subunit of FoF1-ATP 
synthase[34].  
To improve specificity of the cellular distribution of the hydrophobic Bz-423 derivatives and to 
accelerate an uptake into mitochondria, attaching cationic dyes could be used. As shown by H. W. 
Zimmermann and coworkers[40-43], almost all fluorophores being lipophilic cations transfer quickly 
to the inner mitochondrial membrane. There, they can bind to proteins. One identified target was 
cytochrome C oxidase. This finding could be used to specifically induce photodamage by singlet oxygen 
as a reactive oxygen species[44-46] for Photodynamic Therapy. Beside photoaffinity labeling 
approaches, time-resolved FRET was applied to reveal that cytochrome C oxidase was a binding site of 
these lipophilic cationic photosensitizers acting as FRET donors[46, 47]. Similarly, confocal imaging 
FRET donor lifetimes of mitochondrial FoF1-ATP synthases in the presence and absence of FRET 
acceptor-tagged Bz-423 derivatives could be employed to provide direct optical evidence for Bz-423 
binding to FoF1. 
FRET-based direct evidence for Bz-423 acting at the mitochondrial FoF1-ATP synthase needs to be 
complemented by detailed analysis of cristae morphology changes. In mitochondria of living cells, this 
can be accomplished by superresolution microscopy approaches, for example structured illumination 
microscopy[28] (SIM) or stimulated emission depletion[48] (STED) microscopy. Especially, a 
rearrangement of row assembly of dimeric FoF1-ATP synthases at the rim of the cristae could indicate 
the beginning and early events of apoptosis. Finally an unequivocal mechanistic demonstration of how 
Bz-423 affects the catalytic activity and the rotary motors of mitochondrial FoF1-ATP synthase is 
awaited. Single-molecule FRET between different fluorophores attached to rotor and stator of the 
mitochondrial enzyme has already been developed. Accordingly, the inhibition mechanism of Bz-423 
could be unraveled by single-molecule rotation experiments, as shown previously for the inhibitor 
Aurovertin[49] or of phytopolyphenols[50].  
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